| |
Course Description
Target Audience
This educational program is intended for physicians, laboratory technologists and other healthcare professionals with special education and training in microbiology or infectious diseases who are interested in the identification, diagnosis, and management of fungal infections.
Educational Objectives
After successful completion of this program participants should be able to:
- List and identify the most important newly emerging fungal pathogens
- Discuss the relevance of clinical laboratory findings for the diagnosis and management of patients with invasive fungal infections
- Recommend treatment for invasive fungal infections in normal and at-risk populations
- Summarize the characteristics of the newer antifungal agents and clinical trial results utilizing these agents
- Comment on fungal infections in non-human species and their relevance to the advances in human fungal infections.
- Comment on challenges in diagnosis and management of fungal infections through challenging case examples
- Discuss the status of clinical trials assessing the feasibility of combination and sequential antifungal therapeutic regimens
Physicians:
Imedex®, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex®, Inc designates this educational activity for a maximum 12 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credits will be awarded upon completion and submission of the self-assessment questions, evaluation form, and CME credit request form to:
Imedex®, Inc.
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751 7334
Deadline for CME Credit submission: April 30, 2008
Unapproved and Investigational Uses of Drugs and Devices
This webcast may contain information about experimental and other uses of drugs or devices that are not currently approved by the Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex®, Inc. or Merck & Co., Inc.
Corporate Support
This webcast is supported by an unrestricted educational grant from Merck & Co., Inc.
Event Organizer
Imedex®, Inc.
4325 Alexander Drive
Alpharetta, GA 30022
Tel.: +1 (770) 751 7332
Fax: +1(770) 751 7334
Disclosure of Financial Interests
As an accredited provider of Continuing Medical Education, Imedex®, Inc. is required to ask speakers to disclose any real or apparent conflict of interest they may have as related to the contents of their presentation(s). The existence of commercial or financial interests of speakers related to the subject matter of their presentation(s) should not be construed as implying bias or decreasing the value of their presentation(s). However, disclosure should help participants form their own judgments.
All speakers were independently selected by the organizing committee. Those speakers who disclosed affiliations or financial interests with the commercial organizations involved with products, to which they may refer, are listed below.
1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
George L. Drusano, MD - RJWPRD1,2
John E. Edwards, Jr., MD - National Institute of Health1
John R. Graybill, MD - F2G1
Kieren A. Marr, MD - Bugilea2, Nektar Therapeutics2
Luis Ostrosky-Zeichner, MD, FACP - ACC1, Rockey1
Coleman M.F. Rotstein, MD, FRCPC, FACP -
Bayer2, Johnson & Johnson1, Wyeth Pharmaceuticals1,2,3
Jack D. Sobel, MD - KU Pharmaceuticals3, Quidel2, Tend Johnson1
The following speakers have reported an affiliation with the supporters of this conference:
David R. Andes, MD - Astellas Pharma, Inc.1, Merck & Company2,3, Pfizer, Inc.1,2,3, Schering Plough2,3
William E. Dismukes, MD - Enzon3, Merck & Company3, Pfizer, Inc.3
John E. Edwards, Jr., MD - Astellas Pharma, Inc.1, Merck & Company1,2, Pfizer, Inc.1,2
John R. Graybill, MD - Merck & Company1,2,3, Schering Plough1,2,3
Paul O. Gubbins, PharmD - Astellas Pharma, Inc.1, Pfizer, Inc.1
James I. Ito, MD - Astellas Pharma, Inc.3, Enzon2,3, Pfizer, Inc.2,3, Schering Plough2,3
William W. Hope, MD - Astellas Pharma, Inc.1
Carol A. Kauffman, MD - Astellas Pharma, Inc.1,3, Merck & Company1,3, Pfizer, Inc.3, Schering Plough1,3
Kieren A. Marr, MD - Astellas Pharma, Inc.1,2, Enzon2, Merck & Company2, Pfizer, Inc.2, Schering Plough1,2
Luis Ostrosky-Zeichner, MD, FACP - Astellas Pharma, Inc.1,2,3, Merck & Company1,3, Pfizer, Inc.1,2,3
John R. Perfect, MD - Astellas Pharma, Inc.1,2,3, Enzon1,2,3, Merck & Company1,2,3, Pfizer, Inc.1,2,3, Schering Plough1,2,3
Michael A. Pfaller, MD - Astellas Pharma, Inc.1,2,3, Merck & Company1,2,3, Pfizer, Inc.1,2,3, Schering Plough1,2,3
Coleman M.F. Rotstein, MD, FRCPC, FACP - Astellas Pharma, Inc.1,2, Merck & Company1,2,3, Pfizer, Inc.1,2,3
Brahm H. Segal, MD - Enzon1,2, Merck & Company3, Pfizer, Inc.2,3, Schering Plough2
Jack D. Sobel, MD - Astellas Pharma, Inc.1, Merck & Company1,2,3, Pfizer, Inc.1,3
John R. Wingard, MD - Merck & Company1,2,3, Pfizer, Inc.1,2,3, Schering Plough2
The following speakers do not report any affiliation:
Robert W. Bradsher, MD
Annette W. Fothergill, MA, MBA
Shigeru Kohno, MD, PhD
Dimitrios P. Kontoyiannis, MD, ScD
Marcio Nucci, MD, PhD
Benjamin J. Park, MD
Michael G. Rinaldi, PhD
David A. Stevens, MD
Deanna A. Sutton, PhD
Ronald C. Walker, MD
The following speakers did not return their disclosure forms:
Elias J. Anaissie, MD
Jay A. Fishman, MD
Mahmoud Ghannoum, PhD, EMBA
Peter G. Pappas, MD
Jan E. Patterson, MD
Thomas F. Patterson, MD, FACP
Thomas J. Walsh, MD
Imedex, Inc. Staff Disclosure of Financial Relationships
All Imedex®, Inc. staff members who are in a position to control the content of this activity have no financial relationships with any commercial interests that are relevant to this activity.
Imedex®, Inc. is an independent provider of Continuing Medical Education. Imedex®, Inc. has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.
©2007 Imedex®, Inc. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
Systems Requirements
- Pentium 500 processor or greater
- Windows 98/NT/2000/XP or Mac OS 9/X
- Microsoft Internet Explorer 5.5 or later
- Windows Media Player 9.0 or later
- 128 MB of RAM
- Monitor settings: High color at 800 x 600 pixels
- Sound card and speakers
- Abstracts require Adobe Acrobat Reader
Audio troubleshooting
For general troubleshooting concerning audio or video playback issues consult the following web link: http://support.microsoft.com/kb/306317.
For questions or comments regarding the content or performance of this webcast please contact Imedex at meetings@imedex.com. |
|
